Skip to content

Study · Ex vivo tissue · 1996

2 results

The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor.

Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ

Cancer research1 May 1996Cited by 58 (Europe PMC)

PMID8616851 (opens in a new tab)PepBankPUB-08616851
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In lab tests, goserelin radioligand assays detected no pituitary-like high-affinity binding sites in endometrial cancer cells or tissues.

    In plain wordsIn lab tests, goserelin assays detected no pituitary-like high-affinity binding sites in endometrial cancer cells or tissues.

    Peptide
    Goserelin
    Outcome
    Not applicableHigh-affinity binding
    Study

    humann: not reported in source

    Endometrial cancer tissues
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In radioligand binding assays using GnRHa goserelin, no pituitary-like, high-affinity GnRH binding sites could be found in either EC cell lines or tissues.
    1 context sentence
    Summary · context
    We have sought the expression of the GnRH peptide and functional GnRH receptor (GnRH-R) in human tissues and cell lines to investigate the possibility of an autocrine growth regulation mechanism.
  2. 02LabEx vivo tissueActivity measurement

    In lab tests, low-affinity goserelin binding occurred in three of eight endometrial cancer tissues, with Kd of 1.0 - 3.1 x 10(-7)M.

    In plain wordsIn lab tests, goserelin showed low-affinity binding in three of eight endometrial cancer tissues.

    Peptide
    Goserelin
    Outcome
    Not applicableLow-affinity binding
    Study

    humann: not reported in source

    Endometrial cancer tissues
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Kd
    1 to 3.1 x 10(-7)M
    endometrial cancer tissues
    Tissues with binding
    37%
    endometrial cancer tissues

    Source sentences

    Summary
    Low affinity binding (Kd = 1.0 - 3.1 x 10(-7)M) was detected in three of eight (37%) EC tissues.
    2 context sentences
    Summary · context
    In radioligand binding assays using GnRHa goserelin, no pituitary-like, high-affinity GnRH binding sites could be found in either EC cell lines or tissues.
    Summary · context
    We have sought the expression of the GnRH peptide and functional GnRH receptor (GnRH-R) in human tissues and cell lines to investigate the possibility of an autocrine growth regulation mechanism.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.